Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
NB
MCID: NRB001
MIFTS: 66

Neuroblastoma (NB)

Categories: Cancer diseases, Endocrine diseases, Fetal diseases, Genetic diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Neuroblastoma

About this section

MalaCards integrated aliases for Neuroblastoma:

Name: Neuroblastoma 12 74 20 43 58 36 29 6 42 44 15 39 17 71
Nb 20 43
Central Neuroblastoma 71
Neuroblastomas 15

Characteristics:

Orphanet epidemiological data:

58
neuroblastoma
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: Childhood; Age of death: adolescent,late childhood;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases Genetic diseases Fetal diseases
Anatomical: Neuronal diseases Endocrine diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:769
KEGG 36 H00043
MeSH 44 D009447
NCIt 50 C3270
SNOMED-CT 67 432328008
MESH via Orphanet 45 C536408 D009447
ICD10 via Orphanet 33 C74.9
UMLS via Orphanet 72 C0027819 C2931189
Orphanet 58 ORPHA635
SNOMED-CT via HPO 68 126950007
UMLS 71 C0027819 C0700095
Sources

Summaries for Neuroblastoma

About this section
MedlinePlus : 42 What is neuroblastoma? Neuroblastoma is a type of cancer that forms in nerve cells called neuroblasts. Neuroblasts are immature nerve tissue. They normally turn into working nerve cells. But in neuroblastoma, they form a tumor. Neuroblastoma usually begins in the adrenal glands. You have two adrenal glands, one on top of each kidney. The adrenal glands make important hormones that help control heart rate, blood pressure, blood sugar, and the way the body reacts to stress. Neuroblastoma may also begin in the neck, chest or spinal cord. What causes neuroblastoma? Neuroblastoma is caused by mutations (changes) in genes. In most cases, the cause of the mutation is unknown. In some other cases, the mutation is passed from the parent to the child. What are the symptoms of neuroblastoma? Neuroblastoma often begins in early childhood. Sometimes it begins before a child is born.The most common symptoms are caused by the tumor pressing on nearby tissues as it grows or by cancer spreading to the bone.They include A lump in the abdomen, neck or chest Bulging eyes Dark circles around the eyes Bone pain Swollen stomach and trouble breathing in babies Painless, bluish lumps under the skin in babies Inability to move a body part (paralysis) How is neuroblastoma diagnosed? To diagnose neuroblastoma, your child's health care provider will do various tests and procedures, which may include A medical history A neurological exam Imaging tests, such as x-rays, a CT scan, an ultrasound, an MRI, or an MIBG scan. In an MIBG scan, a small amount of a radioactive substance is injected into a vein. It travels through the bloodstream and attaches itself to any neuroblastoma cells. A scanner detects the cells. Blood and urine tests Biopsy, where a sample of tissue is removed and examined under a microscope Bone marrow aspiration and biopsy, where bone marrow, blood, and a small piece of bone are removed for testing What are the treatments for neuroblastoma? The treatments for neuroblastoma include: Observation, also called watchful waiting, where the health care provider does not give any treatments until your child's signs or symptoms appear or change Surgery Radiation therapy Chemotherapy High-dose chemotherapy and radiation therapy with stem cell rescue. Your child will get high doses of chemotherapy and radiation. This kills the cancer cells, but it also kills healthy cells. So your child will get a stem cell transplant, usually of his or her own cells collected earlier. This helps to replace the healthy cells that were lost. Iodine 131-MIBG therapy, a treatment with radioactive iodine. The radioactive iodine collects in neuroblastoma cells and kills them with the radiation that is given off. Targeted therapy, which uses drugs or other substances that attack specific cancer cells with less harm to normal cells NIH: National Cancer Institute

MalaCards based summary : Neuroblastoma, also known as nb, is related to medulloblastoma and glioma, and has symptoms including seizures, tremor and back pain. An important gene associated with Neuroblastoma is ALK (ALK Receptor Tyrosine Kinase), and among its related pathways/superpathways are Transcriptional misregulation in cancer and LncRNA-mediated mechanisms of therapeutic resistance. The drugs Lenograstim and Nicotine have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, bone and brain, and related phenotypes are neoplasm of the nervous system and elevated urinary catecholamines

Disease Ontology : 12 An autonomic nervous system neoplasm that derives from immature nerve cells.

MedlinePlus Genetics : 43 Neuroblastoma is a type of cancer that most often affects children. Neuroblastoma occurs when immature nerve cells called neuroblasts become abnormal and multiply uncontrollably to form a tumor. Most commonly, the tumor originates in the nerve tissue of the adrenal gland located above each kidney. Other common sites for tumors to form include the nerve tissue in the abdomen, chest, neck, or pelvis. Neuroblastoma can spread (metastasize) to other parts of the body such as the bones, liver, or skin.Individuals with neuroblastoma may develop general signs and symptoms such as irritability, fever, tiredness (fatigue), pain, loss of appetite, weight loss, or diarrhea. More specific signs and symptoms depend on the location of the tumor and where it has spread. A tumor in the abdomen can cause abdominal swelling. A tumor in the chest may lead to difficulty breathing. A tumor in the neck can cause nerve damage known as Horner syndrome, which leads to drooping eyelids, small pupils, decreased sweating, and red skin. Tumor metastasis to the bone can cause bone pain, bruises, pale skin, or dark circles around the eyes. Tumors in the backbone can press on the spinal cord and cause weakness, numbness, or paralysis in the arms or legs. A rash of bluish or purplish bumps that look like blueberries indicates that the neuroblastoma has spread to the skin.In addition, neuroblastoma tumors can release hormones that may cause other signs and symptoms such as high blood pressure, rapid heartbeat, flushing of the skin, and sweating. In rare instances, individuals with neuroblastoma may develop opsoclonus myoclonus syndrome, which causes rapid eye movements and jerky muscle motions. This condition occurs when the immune system malfunctions and attacks nerve tissue.Neuroblastoma occurs most often in children before age 5 and rarely occurs in adults.

GARD : 20 Neuroblastoma is a tumor that develops from neuroblasts (immature nerve tissue) in an infant or child, usually before the age of 5. It most often develops in infancy and may be diagnosed in the first month of life. The tumor most often develops in the adrenal gland, but may develop in the neck, chest, or spinal cord. It is considered an aggressive tumor because it often spreads to other parts of the body (metastasizes). In most cases, it has spread by the time it is diagnosed. A neuroblastoma can cause a variety of signs and symptoms, including a lump where the tumor is growing, bone pain, diarrhea, and various neurological symptoms. The cause of most neuroblastomas is not known. Rarely, a neuroblastoma is caused by an inherited mutation in a gene, such as the ALK gene or PHOX2B gene. Diagnosing a neuroblastoma may rely on a physical examination, blood tests, imaging tests (such as MRI or CT scan) and ultimately, a biopsy. Treatment depends on the size and location of the tumor within the body, as well as the child's age. Surgery is often the first step of treatment, and may be followed by chemotherapy, radiation therapy, or a stem cell transplant in more severe cases. In some children the tumor goes away without treatment. While the long-term outlook and chance of survival depends on many factors, the 5-year survival rate ranges from 40-50% in some, to over 95% in others. The child's doctor is in the best position to provide personalized information about the outlook in each case.

KEGG : 36 Neuroblastoma is a tumor derived from primitive cells of the sympathetic nervous system and is the most common solid tumor in childhood. Approximately one-half of children have localized tumors that can be cured with surgery alone. These favorable tumors are characterized by near-triploid karyotypes with whole chromosome gains. These tumors rarely have structural rearrangements, and they usually express the TrkA neurotrophin receptor. Patients with these tumors are more likely to be less than 1 year of age. The remaining children have widespread metastatic disease or quite large, aggressive, localized tumors. These unfavorable tumors are characterized by structural changes, including deletions of 1p or 11q, unbalanced gain of 17q and/or amplification of the MYCN protooncogene. They might also express the TrkB neurotrophin receptor and its ligand, brain-derived neurotrophic factor (BDNF). These patients are usually older than 1 year of age, and have a poor long-term survival rate of approximately 30%.

Wikipedia : 74 Neuroblastoma (NB) is a type of cancer that forms in certain types of nerve tissue. It most frequently... more...

Sources

Related Diseases for Neuroblastoma

About this section

Diseases in the Neuroblastoma family:

Neuroblastoma 1 Neuroblastoma 2
Neuroblastoma 3 Neuroblastoma 4
Neuroblastoma 5 Neuroblastoma 6
Neuroblastoma 7

Diseases related to Neuroblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1147)
# Related Disease Score Top Affiliating Genes
1 medulloblastoma 32.1 MYCNOS MIR34A MIR17 HOTAIR H19 ALK
2 glioma 31.3 MIR34A MIR184 MIR17 MEG3 MALAT1 HOTAIR
3 nodular ganglioneuroblastoma 31.1 MYCNOS ALK
4 glioblastoma 31.1 MYCNOS MIR34A MEG3 MALAT1 HOTAIR H19
5 b-cell lymphoma 30.8 MIR34A MIR17 MALAT1 HOTAIR GAS5 ALK
6 osteogenic sarcoma 30.7 SNHG1 MEG3 MALAT1 HOTAIR H19 GAS5
7 renal cell carcinoma, nonpapillary 30.7 NBAT1 MIR34A MIR17 MALAT1 HOTAIR H19
8 thyroid carcinoma 30.5 MALAT1 HOTAIR H19 GAS5
9 small cell cancer of the lung 30.4 MALAT1 HOTAIR ALK
10 leukemia, acute myeloid 30.3 MIR34A MIR184 MIR17 MEG3 MALAT1 HOTAIR
11 pituitary adenoma 30.3 MEG3 MALAT1 HOTAIR H19
12 melanoma 30.2 PAUPAR MIR34A MIR184 MIR17 MEG3 MALAT1
13 thyroid cancer, nonmedullary, 1 30.1 MEG3 MALAT1 HOTAIR H19
14 nasopharyngeal carcinoma 30.0 MIR17 MEG3 MALAT1 HOTAIR H19 GAS5
15 high grade glioma 30.0 MEG3 MALAT1 HOTAIR H19 GAS5
16 lung cancer susceptibility 3 30.0 MIR17 MEG3 MALAT1 HOTAIR H19 GAS5
17 myeloma, multiple 29.9 MIR17 MEG3 MALAT1 HOTAIR H19 GAS5
18 retinitis pigmentosa 11 29.8 HOTAIR GAS5 ALK
19 bladder cancer 29.8 SNHG16 MIR34A MIR17 MEG3 MALAT1 HOTAIR
20 leukemia, chronic myeloid 29.7 MIR17 MEG3 HOTAIR H19
21 ovarian cancer 29.7 SNHG16 NBAT1 MIR34A MIR17 MEG3 MALAT1
22 liver cirrhosis 29.4 MEG3 MALAT1 HOTAIR GAS5
23 hepatocellular carcinoma 29.2 SNHG1 MIR34A MIR17 MEG3 MALAT1 HOTAIR
24 prostate cancer 28.9 SNHG1 MIR34A MIR184 MIR17 MEG3 MALAT1
25 neuroblastoma 1 11.6
26 olfactory neuroblastoma 11.5
27 neuroblastoma 2 11.5
28 neuroblastoma 3 11.4
29 adrenal neuroblastoma 11.3
30 cerebral neuroblastoma 11.3
31 cervical neuroblastoma 11.3
32 retinoblastoma 11.3
33 differentiating neuroblastoma 11.2
34 nasal cavity olfactory neuroblastoma 11.2
35 spinal cord neuroblastoma 11.2
36 neuroblastoma 4 11.1
37 neuroblastoma 5 11.1
38 extracranial neuroblastoma 11.1
39 neuroblastoma 6 11.1
40 retroperitoneal neuroblastoma 11.1
41 adrenal carcinoma 11.1
42 ganglioneuroblastoma 11.1
43 neuroblastoma 7 11.1
44 central hypoventilation syndrome, congenital 11.0
45 weaver syndrome 11.0
46 mediastinum neuroblastoma 11.0
47 simpson-golabi-behmel syndrome 11.0
48 wilms tumor 1 11.0
49 opsoclonus-myoclonus syndrome 11.0
50 hirschsprung disease ganglioneuroblastoma 10.9

Graphical network of the top 20 diseases related to Neuroblastoma:



Diseases related to Neuroblastoma
Sources

Symptoms & Phenotypes for Neuroblastoma

About this section

Human phenotypes related to Neuroblastoma:

58 31
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 neoplasm of the nervous system 58 31 hallmark (90%) Very frequent (99-80%) HP:0004375
2 elevated urinary catecholamines 58 31 hallmark (90%) Very frequent (99-80%) HP:0011976

UMLS symptoms related to Neuroblastoma:


seizures, tremor, back pain, headache, syncope, pain, chronic pain, sciatica, vertigo/dizziness, sleeplessness
Sources

Drugs & Therapeutics for Neuroblastoma

About this section

Drugs for Neuroblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 348)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 4 135968-09-1
2
Nicotine Approved Phase 4 54-11-5 942 89594
3
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
4
Trametinib Approved Phase 4 871700-17-3 11707110
5
Dabrafenib Approved, Investigational Phase 4 1195765-45-7 44462760 44516822
6 Adjuvants, Immunologic Phase 4
7 Cytochrome P-450 Enzyme Inhibitors Phase 4
8 Cytochrome P-450 CYP3A Inhibitors Phase 4
9
Hydroxyitraconazole Phase 4 108222
10
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
11
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
12
Vindesine Approved, Investigational Phase 3 53643-48-4, 59917-39-4 40839
13
Dacarbazine Approved, Investigational Phase 3 4342-03-4 5351166 2942
14
carbamide peroxide Approved Phase 2, Phase 3 124-43-6
15
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
16
Furosemide Approved, Vet_approved Phase 3 54-31-9 3440
17
Isotretinoin Approved Phase 3 4759-48-2 5538 5282379
18
rituximab Approved Phase 3 174722-31-7 10201696
19
Topotecan Approved, Investigational Phase 3 119413-54-6, 123948-87-8 60700
20
Crizotinib Approved Phase 3 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
21
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
22
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
23
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
24
Melphalan Approved Phase 2, Phase 3 148-82-3 4053 460612
25
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
26
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
27
Moxifloxacin Approved, Investigational Phase 3 151096-09-2, 354812-41-2 152946
28
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
29
Polyestradiol phosphate Approved Phase 3 28014-46-2
30
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 5538 444795
31
Phenylalanine Approved, Investigational, Nutraceutical Phase 3 63-91-2 6140
32
Tyrosine Approved, Investigational, Nutraceutical Phase 3 60-18-4 6057
33
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 68-26-8, 11103-57-4 445354
34 Melanocyte-Stimulating Hormones Phase 3
35 Adrenocorticotropic Hormone Phase 3
36 beta-Endorphin Phase 3
37 Corticotropin-Releasing Hormone Phase 3
38 Endorphins Phase 3
39 Calcium, Dietary Phase 3
40 Calamus Phase 3
41 Antidotes Phase 3
42 Antioxidants Phase 3
43 sodium thiosulfate Phase 3
44 Radiopharmaceuticals Phase 3
45 Iron-Dextran Complex Phase 3
46 Neurotransmitter Agents Phase 3
47 Dihydroxyphenylalanine Phase 3
48 Dopamine Agents Phase 3
49 diuretics Phase 3
50 Sodium Potassium Chloride Symporter Inhibitors Phase 3

Interventional clinical trials:

(show top 50) (show all 524)
# Name Status NCT ID Phase Drugs
1 A Single Arm, Multi-center Study to Assess the Efficacy and Safety of Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in Non-squamous Non-small-cell Lung Cancer (NSCLC) Unknown status NCT03799601 Phase 4 Anlotinib;Docetaxel;Carboplatin
2 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor: a Prospective, Multicentre, Randomised Controlled Trial Unknown status NCT02933333 Phase 4
3 Clinical Study to Evaluate the Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Pediatric Solid Tumors Completed NCT00336531 Phase 4 itraconazole
4 An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Recruiting NCT03975829 Phase 4 dabrafenib;trametinib
5 UKCCSG Stage IIB/3 (INSS) Neuroblastoma Pilot Study [ENSG VI (Pilot 2B/3)] Unknown status NCT00416676 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;vincristine sulfate
6 Randomized Study of Radiotherapy in Patients With Stage 2B/3 (INSS) Neuroblastoma in Children Over 1 Year of Age Unknown status NCT00276731 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;vincristine sulfate
7 High Risk Neuroblastoma Study 1 Of Siop-Europe Unknown status NCT00030719 Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;isotretinoin;melphalan;vincristine sulfate
8 NB2004 Trial Protocol for Risk Adapted Treatment of Children With Neuroblastoma Unknown status NCT00410631 Phase 3 carboplatin;cisplatin;cyclophosphamide;dacarbazine;doxorubicin hydrochloride;etoposide phosphate;ifosfamide;isotretinoin;melphalan;topotecan hydrochloride;vincristine sulfate;vindesine
9 European Infant Neuroblastoma Study Final Protocol Unknown status NCT00417053 Phase 3 busulfan;carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide phosphate;melphalan;vincristine sulfate
10 A Pilot Study Randomized Trial of Intravenous Gammaglobulin Therapy for Patients With Neuroblastoma Associated Opsoclonus-Myoclonus-Ataxia Syndrome Treated With Chemotherapy and Prednisone Unknown status NCT00033293 Phase 3 cyclophosphamide;prednisone;Corticotropin-Releasing Hormone
11 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3 123I-meta-iodobenzylguanidine
12 Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-risk Neuroblastoma Completed NCT03042429 Phase 3 Cycles N8, N5 and N6;Cycles N5 and N6
13 Treatment Of Children Over The Age Of 1 Year With Unresectable Localized Neuroblastoma Without MYCN Amplification Completed NCT00025428 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
14 Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study Completed NCT00003119 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide
15 A Randomized Study of Purged Versus Unpurged Peripheral Blood Stem Cell Transplant Following Dose Intensive Induction Therapy for High Risk Neuroblastoma Completed NCT00004188 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;isotretinoin;melphalan;topotecan hydrochloride;vincristine sulfate
16 Comparison of High Dose Rapid Schedule With Conventional Schedule Chemotherapy for Stage 4 Neuroblastoma Over the Age of One Year Completed NCT00365755 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;melphalan;vincristine sulfate
17 Treatment for Infants and Children With Intermediate Risk Neuroblastoma: A Phase III Intergroup CCG/POG Study Completed NCT00003093 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide
18 PHASE III MULTICENTRE TRIAL OF TREATMENT OF NEUROBLASTOMA IN CHILDREN AND ADOLESCENTS Completed NCT00002802 Phase 3 carboplatin;cisplatin;cyclophosphamide;dacarbazine;doxorubicin hydrochloride;etoposide;ifosfamide;melphalan;mesna;vincristine sulfate;vindesine
19 An Open-Label, Multicentre, Phase 3 Scintigraphy Study Assessing 123I-mIBG Uptake in Subjects Being Evaluated for Phaeochromocytoma or Neuroblastoma Completed NCT00126412 Phase 3 123I-mIBG (meta-iodobenzylguanidine)
20 A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in Children Completed NCT00716976 Phase 3 sodium thiosulfate
21 A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
22 HSCT-CHESS to Enhance Hematopoietic Transplant Recovery Completed NCT00782145 Phase 3
23 INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation Completed NCT00799461 Phase 3
24 High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN) Recruiting NCT01704716 Phase 3 Vincristine;Aldesleukin;ch14.18/CHO;Carboplatin;Etoposide;Cisplatin;Cyclophosphamide;Doxorubicin;G-CSF;Busulfan;Melphalan
25 High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) Recruiting NCT04221035 Phase 3 Vincristine;Carboplatin;Etoposide;Cyclophosphamide;Vindesine;Dacarbazine;Ifosfamide;Doxorubicin;Busulfan;Melphalan;Thiotepa;Dinutuximab Beta;Cisplatin
26 European Low and Intermediate Risk Neuroblastoma Protocol Recruiting NCT01728155 Phase 3 chemotherapy
27 A Multicenter Phase 2/3 Trial of the Efficacy and Safety of Intracerebroventricular Radioimmunotherapy Using 131I-omburtamab for Neuroblastoma Central Nervous System/Leptomeningeal Metastases Recruiting NCT03275402 Phase 2, Phase 3
28 Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma Recruiting NCT02176967 Phase 3 Carboplatin;Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide
29 18F-DOPA II - PET Imaging Optimization Recruiting NCT04706910 Phase 3 18F-DOPA;Furosemide Injection
30 Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma Active, not recruiting NCT00567567 Phase 3 Carboplatin;Cisplatin;Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Isotretinoin;Melphalan;Thiotepa;Topotecan Hydrochloride;Vincristine Sulfate Liposome
31 Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue Active, not recruiting NCT00026312 Phase 3 Isotretinoin
32 A Comprehensive Safety Trial of Chimeric Antibody 14.18 (Ch14.18) With GM-CSF, IL-2 and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy Active, not recruiting NCT01041638 Phase 3 Isotretinoin
33 Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma Active, not recruiting NCT00499616 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;topotecan hydrochloride;Isotretinoin;Filgrastim
34 A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL) Active, not recruiting NCT03126916 Phase 3 Busulfan;Carboplatin;Cisplatin;Crizotinib;Cyclophosphamide;Dexrazoxane Hydrochloride;Doxorubicin Hydrochloride;Etoposide Phosphate;Isotretinoin;Melphalan Hydrochloride;Thiotepa;Topotecan Hydrochloride;Vincristine Sulfate
35 Multinational European Trial for Children With the Opsoclonus Myoclonus Syndrome / Dancing Eye Syndrome Active, not recruiting NCT01868269 Phase 3 Dexamethasone acetate;dexamethasone and cyclophosphamide;dexamethasone and rituximab
36 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety Active, not recruiting NCT03042416 Phase 3 18F-DOPA
37 Irinotecan and Temozolomide With or Without Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor in Patients With High-Risk Neuroblastoma With Primary Refractory Disease or in First Relapse. An International, Open Label, Randomized, Controlled, Two-Arm, Multicenter Phase 3 Trial Not yet recruiting NCT04560166 Phase 3 irinotecan and temozolomide and naxitamab and GM CSF;irinotecan and temozolomide
38 A Prospective Phase 3 Multi-center Study to Assess the Efficacy and Safety of 18F-mFBG PET Imaging in Subjects With Neuroblastoma Not yet recruiting NCT04724369 Phase 3 18F-MFBG
39 Autologous Stem Cell Rescue With CD133+ Selected Hematopoietic Progenitor Cells in Patients With High-Risk Neuroblastoma Terminated NCT00539500 Phase 2, Phase 3 Carboplatin;Etoposide;Melphalan
40 Randomized, Double Blinded, Placebo-Controlled Trial of Antibacterial Prophylaxis for the Prevention of Bacterial Infections in the Post-Engraftment Phase After Allogeneic Hematopoeitic Stem Cell Transplantation Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
41 Prospective and Randomized Study of Fixed Versus Flexible Prophylactic Administration of Granulocyte Colony-Stimulating Factor (G-CSF) in Children With Cancer Terminated NCT01987596 Phase 3
42 An Open-Label, Multicentre, Phase II Study of TVD as Treatment for Children With Stage 4 Neuroblastoma Failing to Respond to First-Line Treatment According to HR-NBL-01/ E-SIOP [Topotecan-Vincristine-Doxorubicin in Children With Stage 4 Neuroblastoma Failing to Respond to COJEC (TVD)] Unknown status NCT00392340 Phase 2 doxorubicin hydrochloride;topotecan hydrochloride;vincristine sulfate
43 Haploidentical Stem Cell Transplantation Followed by NK Cell Infusion in Patients With High-risk Solid Tumors Who Failed Autologous Stem Cell Transplantation Unknown status NCT01807468 Phase 2
44 Phase 2 Study of Anti-angiogenetic Therapy With Radiotherapy for Pediatric Neuroblastoma Unknown status NCT02615106 Phase 2 Endostar
45 Phase II Single Arm Study to Assess Dinutuximab (Ch 14.18) Combined With the Cytokines Granulocyte-macrophage Colony Stimulating Factor (GM-CSF) and IL-2 in Patients With High-risk Neuroblastoma Not Eligible to Other Immunotherapy Trials Unknown status NCT02169609 Phase 2 Dinutuximab. Immunotherapy
46 A Study Of The Treatment Of Metastatic Neuroblastoma In Children More Than One Year Of Age At Diagnosis Unknown status NCT00024193 Phase 2 busulfan;cisplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;melphalan;vincristine sulfate
47 Treatment of Neuroblastoma and GD2-Positive Tumors With Activated T Cells Armed With OKT3 X Humanized 3F8 Bispecific Antibodies (GD2Bi): A Phase I/II Study Unknown status NCT02173093 Phase 1, Phase 2
48 Multicenter Observer-Blind Randomized Phase II Parallel Study Comparing Three Doses of Subcutaneous Interleukin 2 After Megatherapy and Peripheral Stem Cell Reinfusion in Stage 4 Neuroblastoma in Patients Over 1 Year of Age Unknown status NCT00003743 Phase 2
49 Haplo-identical Hematopoietic Stem Cell Transplantation Following Reduced-intensity Conditioning in Children With Neuroblastoma Unknown status NCT01156350 Phase 2 Busulfan - Fludarabine - TBI
50 CHP677: I-Metaiodobenzylguanidine (I-MIBG) Therapy for Refractory Neuroblastoma: a Phase II Study Unknown status NCT00013806 Phase 2 131I-MIBG

Search NIH Clinical Center for Neuroblastoma

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Cisplatin
CISPLATIN PWDR
Cyclophosphamide
Dacarbazine
Etoposide
etoposide phosphate
Isotretinoin
Melphalan
Melphalan hydrochloride
Vincristine
Vincristine Sulfate

Cochrane evidence based reviews: neuroblastoma

Sources

Genetic Tests for Neuroblastoma

About this section

Genetic tests related to Neuroblastoma:

# Genetic test Affiliating Genes
1 Neuroblastoma 29
Sources

Anatomical Context for Neuroblastoma

About this section

MalaCards organs/tissues related to Neuroblastoma:

40
Bone Marrow, Bone, Brain, T Cells, Adrenal Gland, Spinal Cord, Thyroid
Sources

Publications for Neuroblastoma

About this section

Articles related to Neuroblastoma:

(show top 50) (show all 31349)
# Title Authors PMID Year
1
ALK germline mutations in patients with neuroblastoma: a rare and weakly penetrant syndrome. 61 6
22071890 2012
2
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. 6 61
18923523 2008
3
Oncogenic mutations of ALK kinase in neuroblastoma. 6 61
18923524 2008
4
Activating mutations in ALK provide a therapeutic target in neuroblastoma. 6 61
18923525 2008
5
Identification of ALK as a major familial neuroblastoma predisposition gene. 6 61
18724359 2008
6
PHOX2B analysis in non-syndromic neuroblastoma cases shows novel mutations and genotype-phenotype associations. 61 6
16691592 2006
7
Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. 61 6
15024693 2004
8
Mixed Findings in Pediatric Neuroblastoma CAR-T Therapy Trial. 42 61
33433565 2021
9
Lineage-Independent Tumors in Bilateral Neuroblastoma. 61 42
33211929 2020
10
Occult olfactory neuroblastoma presenting with multiple bone metastases: a case report. 61 42
33235061 2020
11
MicroRNA mediates DNA demethylation events triggered by retinoic acid during neuroblastoma cell differentiation. 61 47
20841484 2010
12
MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. 61 47
19584290 2009
13
Post-transcriptional regulation of mouse mu opioid receptor (MOR1) via its 3' untranslated region: a role for microRNA23b. 61 47
18716031 2008
14
The MYCN oncogene is a direct target of miR-34a. 47 61
18504438 2008
15
A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. 47 61
18505919 2008
16
Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. 61 47
18493594 2008
17
MYCN regulates oncogenic MicroRNAs in neuroblastoma. 61 47
17943719 2008
18
MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. 47 61
17297439 2007
19
The interplay between microRNAs and the neurotrophin receptor tropomyosin-related kinase C controls proliferation of human neuroblastoma cells. 61 47
17483472 2007
20
Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. 47 61
17283129 2007
21
Redox imbalance induced by docetaxel in the neuroblastoma SH-SY5Y cells: a study of docetaxel-induced neuronal damage. 61
33563132 2021
22
MYCN‑amplified neuroblastoma cell‑derived exosomal miR‑17‑5p promotes proliferation and migration of non‑MYCN amplified cells. 61
33537818 2021
23
Temporal trends in childhood cancer survival in Egypt, 2007 to 2017: A large retrospective study of 14 808 children with cancer from the Children's Cancer Hospital Egypt. 61
32997796 2021
24
Guaiane-type sesquiterpenoids from the roots of Stellera chamaejasme L. and their neuroprotective activities. 61
33412403 2021
25
Oxyresveratrol exerts ATF4- and Grp78-mediated neuroprotection against endoplasmic reticulum stress in experimental Parkinson's disease. 61
31100053 2021
26
Prostaglandin A1 Decreases the Phosphorylation of Tau by Activating Protein Phosphatase 2A via a Michael Addition Mechanism at Cysteine 377. 61
33095414 2021
27
Bone marrow necrosis in pediatric malignancies: 10-Year retrospective review and review of literature. 61
33314722 2021
28
NMR-based Lavado cocoa chemical characterization and comparison with fermented cocoa varieties: Insights on cocoa's anti-amyloidogenic activity. 61
33038804 2021
29
CDK5 inhibition protects against OGDR induced mitochondrial fragmentation and apoptosis through regulation of Drp1S616 phosphorylation. 61
33476635 2021
30
Robust Dopaminergic Differentiation and Enhanced LPS-Induced Neuroinflammatory Response in Serum-Deprived Human SH-SY5Y Cells: Implication for Parkinson's Disease. 61
32789724 2021
31
Carnosic acid depends on glutathione to promote mitochondrial protection in methylglyoxal-exposed SH-SY5Y cells. 61
33411218 2021
32
Interactions of Antibodies to the Gram-Negative Gastric Bacterium Helicobacter pylori with the Synaptic Calcium Sensor Synaptotagmin 5, Correlate to Impaired Vesicle Recycling in SiMa Human Neuroblastoma Cells. 61
32860155 2021
33
The reliability of bone marrow cytology as response criterion in metastatic neuroblastoma. 61
33245195 2021
34
The O6-methyguanine-DNA methyltransferase inhibitor O6-benzylguanine enhanced activity of temozolomide + irinotecan against models of high-risk neuroblastoma. 61
33323683 2021
35
Neuroblastoma and the epigenome. 61
33404859 2021
36
NK Cell-mediated Neuroblastoma Cell Lysis is Enhanced by IgG From Patients With Pediatric Opsoclonus-Myoclonus Syndrome. 61
33060390 2021
37
Neonatal Neuroblastoma. 61
33583499 2021
38
Effects of Salvia officinalis L. and Chamaemelum nobile (L.) extracts on inflammatory responses in two models of human cells: Primary subcutaneous adipocytes and neuroblastoma cell line (SK-N-SH). 61
33246119 2021
39
Inhibiting phosphoglycerate dehydrogenase counteracts chemotherapeutic efficacy against MYCN-amplified neuroblastoma. 61
33284994 2021
40
Bilateral Mirror Image Thoracic Neuroblastoma: Unusual Presentation in an Infant. 61
32341260 2021
41
Pulmonary Metastasis of Low-risk Perinatal Neuroblastoma After Resection: Implications for Surveillance. 61
31815890 2021
42
Cell-free DNA Oncogene Copy Number as a Surrogate Molecular Biomarker in ALK/MYCN-coamplified Neuroblastoma. 61
32032241 2021
43
Association between NER pathway gene polymorphisms and neuroblastoma risk in an eastern Chinese population. 61
33575466 2021
44
Neuroblastoma-targeted nanoparticles and novel nanotechnology-based treatment methods. 61
32735058 2021
45
A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high-risk neuroblastoma: An International Neuroblastoma Risk Group project. 61
33205902 2021
46
Tolerance of dinutuximab therapy for treatment of high-risk neuroblastoma in two patients with end-stage renal disease on dialysis. 61
33381917 2021
47
Pencil Beam Scanning Proton Therapy Case Selection for Paediatric Abdominal Neuroblastoma: Effects of Tumour Location and Bowel Gas. 61
32962907 2021
48
Hirsutanol A exhibits neuroprotective activities against sevoflurane-induced neurotoxicity in aged rats. 61
32536020 2021
49
Evaluation of toxicity of gadolinium-based contrast agents on neuronal cells. 61
32366109 2021
50
Dual-Specificity Phosphatase 26 Protects Against Cardiac Hypertrophy Through TAK1. 61
33522247 2021
Sources

Variations for Neuroblastoma

About this section

ClinVar genetic disease variations for Neuroblastoma:

6 (show top 50) (show all 1751)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 ALK NM_004304.5(ALK):c.3383G>C (p.Gly1128Ala) SNV Pathogenic, risk factor 18084 rs113994088 2:29445450-29445450 2:29222584-29222584
2 ALK NM_004304.5(ALK):c.3575G>C (p.Arg1192Pro) SNV Pathogenic, risk factor 18085 rs113994089 2:29443642-29443642 2:29220776-29220776
3 RBM15 NM_022768.4(RBM15):c.1912C>A (p.Gln638Lys) SNV other 438785 rs1553224979 1:110883939-110883939 1:110341317-110341317
4 NTRK2 NM_006180.4(NTRK2):c.970T>A (p.Leu324Met) SNV other 438780 rs201362502 9:87342685-87342685 9:84727770-84727770
5 MAP2K7 NM_145185.4(MAP2K7):c.752T>C (p.Leu251Pro) SNV other 438771 rs1555701191 19:7975941-7975941 19:7911056-7911056
6 MET NM_000245.4(MET):c.985C>A (p.Leu329Ile) SNV other 438775 rs1554378983 7:116340123-116340123 7:116700069-116700069
7 PHF6 NM_001015877.2(PHF6):c.119C>A (p.Ala40Glu) SNV other 438782 rs1556013242 X:133511766-133511766 X:134377736-134377736
8 MAP2K4 NM_003010.4(MAP2K4):c.538C>G (p.Leu180Val) SNV other 438770 rs1555550018 17:12011131-12011131 17:12107814-12107814
9 TSC2 NM_000548.5(TSC2):c.3284+1G>T SNV other 438793 rs45517289 16:2129430-2129430 16:2079429-2079429
10 FGFR3 NM_000142.5(FGFR3):c.991T>C (p.Phe331Leu) SNV other 438762 rs1246952737 4:1805479-1805479 4:1803752-1803752
11 ALK NM_004304.5(ALK):c.3824G>A (p.Arg1275Gln) SNV Pathogenic, risk factor 18083 rs113994087 2:29432664-29432664 2:29209798-29209798
12 BRCA2 NM_000059.3(BRCA2):c.1075G>A (p.Glu359Lys) SNV other 438754 rs1555281730 13:32906690-32906690 13:32332553-32332553
13 ALK NM_004304.5(ALK):c.3824G>A (p.Arg1275Gln) SNV Pathogenic 18083 rs113994087 2:29432664-29432664 2:29209798-29209798
14 ALK NM_004304.5(ALK):c.3749T>C (p.Ile1250Thr) SNV Pathogenic 21867 rs113994092 2:29432739-29432739 2:29209873-29209873
15 ALK NM_004304.5(ALK):c.3512T>C (p.Ile1171Thr) SNV Pathogenic 545115 rs1057519698 2:29445213-29445213 2:29222347-29222347
16 ALK NM_004304.5(ALK):c.3733T>G (p.Phe1245Val) SNV Pathogenic 65671 rs281864720 2:29436860-29436860 2:29213994-29213994
17 ALK NM_004304.5(ALK):c.3735C>G (p.Phe1245Leu) SNV Pathogenic 375885 rs863225284 2:29436858-29436858 2:29213992-29213992
18 ALK NM_004304.5(ALK):c.3520T>G (p.Phe1174Val) SNV Pathogenic 65670 rs281864719 2:29443697-29443697 2:29220831-29220831
19 ALK NM_004304.5(ALK):c.3452C>T (p.Thr1151Met) SNV Pathogenic 18086 rs113994091 2:29445273-29445273 2:29222407-29222407
20 ALK NM_004304.5(ALK):c.3734T>G (p.Phe1245Cys) SNV Pathogenic 217856 rs863225283 2:29436859-29436859 2:29213993-29213993
21 ALK NM_004304.5(ALK):c.3522C>A (p.Phe1174Leu) SNV Pathogenic 217851 rs863225281 2:29443695-29443695 2:29220829-29220829
22 ALK NM_004304.5(ALK):c.3520T>A (p.Phe1174Ile) SNV Pathogenic 217850 rs281864719 2:29443697-29443697 2:29220831-29220831
23 ALK NM_004304.5(ALK):c.3271G>A (p.Asp1091Asn) SNV Pathogenic 218628 rs864309584 2:29446296-29446296 2:29223430-29223430
24 ALK NM_004304.5(ALK):c.3833A>C (p.Tyr1278Ser) SNV Pathogenic 217858 rs863225285 2:29432655-29432655 2:29209789-29209789
25 ALK NM_004304.5(ALK):c.3521T>G (p.Phe1174Cys) SNV Pathogenic 375887 rs1057519697 2:29443696-29443696 2:29220830-29220830
26 ALK NM_004304.5(ALK):c.3512T>A (p.Ile1171Asn) SNV Pathogenic 375888 rs1057519698 2:29445213-29445213 2:29222347-29222347
27 ALK NM_004304.5(ALK):c.3520T>G (p.Phe1174Val) SNV Pathogenic 65670 rs281864719 2:29443697-29443697 2:29220831-29220831
28 ALK NM_004304.5(ALK):c.3733T>G (p.Phe1245Val) SNV Pathogenic 65671 rs281864720 2:29436860-29436860 2:29213994-29213994
29 ALK NM_004304.5(ALK):c.3522C>A (p.Phe1174Leu) SNV Pathogenic 217851 rs863225281 2:29443695-29443695 2:29220829-29220829
30 ALK NM_004304.5(ALK):c.3520T>C (p.Phe1174Leu) SNV Pathogenic 217849 rs281864719 2:29443697-29443697 2:29220831-29220831
31 ALK NM_004304.5(ALK):c.3734T>G (p.Phe1245Cys) SNV Pathogenic 217856 rs863225283 2:29436859-29436859 2:29213993-29213993
32 ALK NM_004304.5(ALK):c.3833A>C (p.Tyr1278Ser) SNV Pathogenic 217858 rs863225285 2:29432655-29432655 2:29209789-29209789
33 ALK NM_004304.5(ALK):c.3733T>A (p.Phe1245Ile) SNV Pathogenic 217855 rs281864720 2:29436860-29436860 2:29213994-29213994
34 ALK NM_004304.5(ALK):c.3520T>A (p.Phe1174Ile) SNV Pathogenic 217850 rs281864719 2:29443697-29443697 2:29220831-29220831
35 ALK NM_004304.5(ALK):c.3522C>G (p.Phe1174Leu) SNV Pathogenic 217852 rs863225281 2:29443695-29443695 2:29220829-29220829
36 ALK NM_004304.5(ALK):c.3735C>A (p.Phe1245Leu) SNV Pathogenic 217857 rs863225284 2:29436858-29436858 2:29213992-29213992
37 PHOX2B NM_003924.3(PHOX2B):c.590G>A (p.Gly197Asp) SNV risk factor 6014 rs104893856 4:41748179-41748179 4:41746162-41746162
38 ALK NM_004304.5(ALK):c.3718T>G (p.Leu1240Val) SNV Likely pathogenic 217854 rs863225282 2:29436875-29436875 2:29214009-29214009
39 FGFR1 NM_023110.2(FGFR1):c.1638C>A (p.Asn546Lys) SNV Likely pathogenic 224896 rs779707422 8:38274849-38274849 8:38417331-38417331
40 TP53 NM_000546.5(TP53):c.843C>G (p.Asp281Glu) SNV Likely pathogenic 376587 rs1057519984 17:7577095-7577095 17:7673777-7673777
41 ALK NM_004304.5(ALK):c.3733T>C (p.Phe1245Leu) SNV Likely pathogenic 376712 rs281864720 2:29436860-29436860 2:29213994-29213994
42 TP53 NM_000546.5(TP53):c.842A>C (p.Asp281Ala) SNV Likely pathogenic 376589 rs587781525 17:7577096-7577096 17:7673778-7673778
43 TP53 NM_000546.5(TP53):c.842A>G (p.Asp281Gly) SNV Likely pathogenic 141141 rs587781525 17:7577096-7577096 17:7673778-7673778
44 PTPN11 NM_002834.4(PTPN11):c.227A>C (p.Glu76Ala) SNV Likely pathogenic 13339 rs121918465 12:112888211-112888211 12:112450407-112450407
45 FGFR1 NM_015850.4(FGFR1):c.1630A>G (p.Asn544Asp) SNV Likely pathogenic 376429 rs1057519898 8:38274851-38274851 8:38417333-38417333
46 ALK NM_004304.5(ALK):c.3520T>C (p.Phe1174Leu) SNV Likely pathogenic 217849 rs281864719 2:29443697-29443697 2:29220831-29220831
47 TP53 NM_000546.5(TP53):c.841G>A (p.Asp281Asn) SNV Likely pathogenic 376586 rs764146326 17:7577097-7577097 17:7673779-7673779
48 PTPN11 NM_002834.4(PTPN11):c.226G>A (p.Glu76Lys) SNV Likely pathogenic 13336 rs121918464 12:112888210-112888210 12:112450406-112450406
49 ALK NM_004304.5(ALK):c.3497T>G (p.Met1166Arg) SNV Likely pathogenic 376713 rs1057520019 2:29445228-29445228 2:29222362-29222362
50 TP53 NM_000546.5(TP53):c.841G>C (p.Asp281His) SNV Likely pathogenic 376588 rs764146326 17:7577097-7577097 17:7673779-7673779

Copy number variations for Neuroblastoma from CNVD:

7 (show top 50) (show all 232)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13319 1 1 124300000 Amplification and loss Neuroblastoma
2 13325 1 1 124300000 Deletion Neuroblastoma
3 13344 1 1 125000000 Copy number Neuroblastoma
4 13349 1 1 125000000 Deletion Neuroblastoma
5 13355 1 1 125000000 Loss Neuroblastoma
6 13407 1 1 2300000 Copy number GNB1 Neuroblastoma
7 13408 1 1 2300000 Copy number SLC35E2A Neuroblastoma
8 13751 1 1 27800000 Loss Neuroblastoma
9 13762 1 1 28000000 Deletion Neuroblastoma
10 13837 1 10001852 10151200 Loss KIF1B Neuroblastoma
11 16476 1 125000000 249250621 Copy number CHD5 Neuroblastoma
12 16477 1 125000000 249250621 Copy number KIF1B Neuroblastoma
13 16597 1 128000000 247249719 Gain Neuroblastoma
14 16598 1 128000000 247249719 Gain Neuroblastoma
15 17283 1 142400000 148000000 Copy number NBPF17P Neuroblastoma
16 17374 1 142600000 147000000 Copy number NBPF1 Neuroblastoma
17 17375 1 142600000 147000000 Copy number NBPF15 Neuroblastoma
18 17376 1 142600000 147000000 Copy number NBPF3 Neuroblastoma
19 18773 1 147305744 147427061 Copy number NBPF1 Neuroblastoma
20 20614 1 153300000 247249719 Gain Neuroblastoma
21 20884 1 155000000 249250621 Gain Neuroblastoma
22 26022 1 195715155 196905060 Gain Neuroblastoma
23 27292 1 206429564 209469901 Gain Neuroblastoma
24 29290 1 2300000 12600000 Loss Neuroblastoma
25 29291 1 2300000 12600000 Loss Neuroblastoma
26 29292 1 2300000 12700000 Loss Neuroblastoma
27 32651 1 3815958 4146056 Amplification DFFB Neuroblastoma
28 32934 1 4056522 10472147 Loss Neuroblastoma
29 33588 1 46500000 51300000 Deletion Neuroblastoma
30 34972 1 5871399 5949729 Loss CHD5 Neuroblastoma
31 36107 1 7200000 16200000 Copy number Neuroblastoma
32 37032 1 84700000 88100000 Deletion Neuroblastoma
33 42798 10 40200000 135534747 Loss Neuroblastoma
34 43291 10 46100000 50100000 Gain Neuroblastoma
35 48305 11 1 10700000 Loss Neuroblastoma
36 48306 11 1 10700000 Loss Neuroblastoma
37 48334 11 1 2800000 Gain Neuroblastoma
38 49040 11 102400000 134452384 Deletion Neuroblastoma
39 49300 11 10515175 10701970 Amplification IRAG1 Neuroblastoma
40 49301 11 10515175 10701970 Amplification RNF141 Neuroblastoma
41 49302 11 10515175 10701970 Amplification LYVE1 Neuroblastoma
42 49698 11 110314720 118319416 Loss Neuroblastoma
43 50154 11 114581997 114912893 Loss CADM1 Neuroblastoma
44 51496 11 12700000 16200000 Copy number SOX6 Neuroblastoma
45 52328 11 16100000 21600000 Deletion Neuroblastoma
46 52785 11 19817525 19848438 Amplification NAV2 Neuroblastoma
47 52827 11 2043796 2201921 Amplification IGF2 Neuroblastoma
48 52828 11 2043796 2201921 Amplification INS Neuroblastoma
49 52829 11 2043796 2201921 Amplification TH Neuroblastoma
50 53355 11 2800000 10700000 Duplication LMO1 Neuroblastoma
Sources

Expression for Neuroblastoma

About this section
Search GEO for disease gene expression data for Neuroblastoma.
Sources

Pathways for Neuroblastoma

About this section

Pathways related to Neuroblastoma according to KEGG:

36
# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202

Pathways related to Neuroblastoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
LncRNA-mediated mechanisms of therapeutic resistance 1
9.7 MEG3 HOTAIR
Sources

GO Terms for Neuroblastoma

About this section

Biological processes related to Neuroblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular response to hypoxia GO:0071456 9.33 MIR34A MIR17 MALAT1
2 negative regulation of vascular endothelial growth factor production GO:1904046 9.32 MIR34A MIR17
3 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.26 MIR17 H19
4 gene silencing by miRNA GO:0035195 9.02 MIR34A MIR184 MIR17 MEG3 H19
5 positive regulation of cardiac muscle cell apoptotic process GO:0010666 8.96 MIR34A MIR17
Sources

Sources for Neuroblastoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....